Project description:Genetic loss of the enzyme 3ß-hydroxysterol-∆24 reductase (DHCR24) results in Desmosterolosis (MIM #602398), a rare disease that presents with multiple congenital anomalies. Earlier studies to create a Dhcr24 global knockout mouse have failed as the pups died within 24 h of birth from lethal dermopathy. We generated a conditional knockout mouse model (Dhcr24flx/flx) and validated it by creating a liver-specific knockout Dhcr24flx/flx, Alb-Cre mouse using a mouse expressing cre recombinase driven by the albumin promoter. Despite increased circulatory and liver desmosterol due to loss of cholesterol synthesis in the liver, these mice demonstrated no marked changes in growth, fertility, hepatic architecture, lipoprotein secretion, etc. RNA-Seq analysis of the female mouse liver revealed no notable perturbations in pathways participating in cholesterol biosynthesis.
Project description:Growth hormone signaling in hepatocytes is fundamentally important. Disruptions in this pathway have led to fatty liver and other metabolic abnormalities. Growth hormone signals through the JAK2/STAT5 pathway. Mice with hepatocyte specific deletion of STAT5 were previously shown to develop fatty liver. Our aim in this study was to determine the effect of deleting JAK2 in hepatocytes on liver gene expression. To do so, we generated animals with hepatocyte specific deletion of JAK2.
Project description:Growth hormone signaling in hepatocytes is fundamentally important. Disruptions in this pathway have led to fatty liver and other metabolic abnormalities. Growth hormone signals through the JAK2/STAT5 pathway. Mice with hepatocyte specific deletion of STAT5 were previously shown to develop fatty liver. Our aim in this study was to determine the effect of deleting JAK2 in hepatocytes on liver gene expression. To do so, we generated animals with hepatocyte specific deletion of JAK2. Hepatocyte-specific JAK2-deficient mice (JAK2L) were generated by mating floxed JAK2 mice (in a mixed (C57Bl/6:129Sv) background) to mice carrying an Alb promoter-regulated Cre transgene on a 100% C57Bl/6 background purchased from the Jackson Labs. Livers were harvested from 8 week old animals for RNA extraction and hybridization.
Project description:The rate-limiting step in glutathione (GSH) synthesis is controlled by glutamate-cysteine ligase catalytic subunit. GSH is reported to buffer oxidative stress. In the absence of GSH, the antioxidant transcription factor Nrf2 is reported to be stabilized. The liver has the highest levels of GSH, but its impact on liver homeostasis is unclear. To investigate this, we induced a liver-specific deletion of Gclc (Gclc f/f), Nrf2 (Nrf2 f/f), or Gclc-Nrf2 (Gclc f/f Nrf2 f/f) by injecting my via tail-vein with AAV-TBG-Cre, which induces recombination specifically in hepatocytes.
Project description:RNA-sequencing analysis of liver gene expression after combinatorial liver-specific deletion of tumor suppressor genes in a mouse fatty liver disease and liver cancer model. Gene expression was determined at 16 weeks of age, before onset of liver tumor formation. Aim was to study how loss of atypical E2F transcription repressors affected gene expression in Pten-mutant livers.
Project description:The effect of liver specific deletion of the insulin receptor substrate-1 (Irs1) and/or Irs2 upon gene expression in the fasted and fed liver of mice; and the effect of liver specific Foxo1 deletion in the Irs1 and Irs2 knockout liver during fasting and feeding.
Project description:Analysis of brown adipose tissue (BAT) isolated from wildtype (WT) and liver kinase B1 (LKB1) deletion mice (Ad/LKB1). Results provide insight into molecular mechanisms underlying paralysis of Ad/LKB1 mice
Project description:The metabolome of plasma and liver lysates of Slc16a13 knockout mice was analyzed. Genome-wide association studies identified SLC16A13 as novel target gene in type 2 diabetes. The SLC16A13 gene encodes for SLC16A13/MCT13, a member of the solute carrier 16 family of monocarboxylate transporters. So far, biology and physiological function of SLC16A13 is unknown. Deletion of Slc16a13 is hypothezised to affect intrahepatocellular monocarboxylate availability, that drives increased oxidative phosphorylation, while reducing hepatic lipid content, thereby attenuating hepatic insulin resistance.